

Nuria Perez-Alvarez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/757068/publications.pdf>

Version: 2024-02-01

86
papers

2,274
citations

201575

27
h-index

233338

45
g-index

88
all docs

88
docs citations

88
times ranked

3485
citing authors

#	ARTICLE	IF	CITATIONS
1	Gut microbiome signatures linked to HIV-1 reservoir size and viremia control. <i>Microbiome</i> , 2022, 10, 59.	4.9	19
2	Prevalence, progression, and management of advanced chronic kidney disease in a cohort of people living with HIV. <i>HIV Medicine</i> , 2022, , .	1.0	0
3	Potential prescribing issues among older HIV-infected subjects in a Mediterranean cohort: Does the current prevalence give cause for concern?. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1310-1317.	1.1	8
4	Effects of integrase inhibitor-based antiretroviral therapy on brain outcomes according to time since acquisition of HIV-1 infection. <i>Scientific Reports</i> , 2021, 11, 11289.	1.6	8
5	Association Between Visceral Abdominal Fat Accumulation and Severity of Liver Fibrosis in Nondiabetic Individuals Coinfected by Human Immunodeficiency Virus and Hepatitis C Virus. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 205-213.	0.5	2
6	A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV. <i>PLoS ONE</i> , 2020, 15, e0238575.	1.1	3
7	Title is missing!. , 2020, 15, e0238575.		0
8	Title is missing!. , 2020, 15, e0238575.		0
9	Title is missing!. , 2020, 15, e0238575.		0
10	Title is missing!. , 2020, 15, e0238575.		0
11	Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study). <i>EClinicalMedicine</i> , 2019, 11, 65-80.	3.2	52
12	NEU Screen Shows High Accuracy in Detecting Cognitive Impairment in Older Persons Living With HIV. <i>Journal of the Association of Nurses in AIDS Care</i> , 2019, 30, 35-41.	0.4	4
13	Simplification of Antiretroviral Treatment from Darunavir/Ritonavir Monotherapy to Darunavir/Cobicistat Monotherapy: Effectiveness and Safety in Routine Clinical Practice. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 513-518.	0.5	20
14	Optimal Use of Transient Elastography and Acoustic Radiation Force Impulse to Stage Liver Fibrosis in HIV/HCV-coinfected Patients in Clinical Practice. <i>Journal of Ultrasound in Medicine</i> , 2018, 37, 113-121.	0.8	4
15	High risk and probability of progression to osteoporosis at 10 years in HIV-infected individuals: the role of PIs. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2452-2459.	1.3	6
16	Variable endothelial cell function restoration after initiation of two antiretroviral regimens in HIV-infected individuals. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2049-2054.	1.3	7
17	Prevalence, evolution, and related risk factors of kidney disease among Spanish HIV-infected individuals. <i>Medicine (United States)</i> , 2017, 96, e7421.	0.4	11
18	Clinical and Emotional Factors Related to Erectile Dysfunction in HIV-Infected Men. <i>American Journal of Men's Health</i> , 2017, 11, 647-653.	0.7	19

#	ARTICLE	IF	CITATIONS
19	Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study. PLoS ONE, 2017, 12, e0182547.	1.1	8
20	Pilot, double-blind, randomized, placebo-controlled clinical trial of the supplement food Nyaditum resae® in adults with or without latent TB infection: Safety and immunogenicity. PLoS ONE, 2017, 12, e0171294.	1.1	14
21	Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B. PLoS ONE, 2017, 12, e0184929.	1.1	13
22	A Multi-state Model for the Progression to Osteopenia and Osteoporosis Among HIV-Infected Patients. Trends in Mathematics, 2017, , 41-45.	0.1	0
23	Prospective Study to Assess Progression of Renal Markers after Interruption of Tenofovir due to Nephrotoxicity. BioMed Research International, 2016, 2016, 1-5.	0.9	7
24	Impact of protease inhibitors on the evolution of urinary markers. Medicine (United States), 2016, 95, e4507.	0.4	4
25	Withdrawing inactive NRTIs in HIV-1 subjects with suppressed viraemia: a randomized trial. Journal of Antimicrobial Chemotherapy, 2016, 71, 1346-1351.	1.3	3
26	Short Communication: Efficacy and Safety of Treatment Simplification to Lopinavir/Ritonavir or Darunavir/Ritonavir Monotherapy: A Randomized Clinical Trial. AIDS Research and Human Retroviruses, 2016, 32, 452-455.	0.5	9
27	In Vivo, Non-Invasive Characterization of Human Bone by Hybrid Broadband (600-1200 nm) Diffuse Optical and Correlation Spectroscopies. PLoS ONE, 2016, 11, e0168426.	1.1	23
28	Monotherapy with boosted PIs as an ART simplification strategy in clinical practice. Journal of Antimicrobial Chemotherapy, 2015, 70, 1124-1129.	1.3	13
29	Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial. Journal of Antimicrobial Chemotherapy, 2015, 70, 1139-1145.	1.3	21
30	Comparison of two different strategies of treatment with zoledronate in HIV-infected patients with low bone mineral density: single dose versus two doses in 2 years. HIV Medicine, 2015, 16, 441-448.	1.0	15
31	Resilience, ageing, and quality of life in long-term diagnosed HIV-infected patients. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2015, 27, 1396-1403.	0.6	38
32	Disability-adjusted-life-years losses in postmenopausal women with osteoporosis: a burden of illness study. BMC Public Health, 2015, 15, 324.	1.2	32
33	Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels. Journal of Antimicrobial Chemotherapy, 2015, 70, 2104-2107.	1.3	25
34	Long-term changes in bone mineral density after switching to a protease inhibitor monotherapy in HIV-infected subject. New Microbiologica, 2015, 38, 193-9.	0.1	3
35	Classification Models for Neurocognitive Impairment in HIV Infection Based on Demographic and Clinical Variables. PLoS ONE, 2014, 9, e107625.	1.1	19
36	Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study). Journal of Antimicrobial Chemotherapy, 2014, 69, 3368-3371.	1.3	43

#	ARTICLE	IF	CITATIONS
37	Prevalence of Ischemic Heart Disease and Management of Coronary Risk in Daily Clinical Practice: Results from a Mediterranean Cohort of HIV-Infected Patients. <i>BioMed Research International</i> , 2014, 2014, 1-8.	0.9	4
38	Peak Bone Mass in Young HIV-Infected Patients Compared With Healthy Controls. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 207-212.	0.9	30
39	High Prevalence of Signs of Renal Damage Despite Normal Renal Function in a Cohort of HIV-Infected Patients: Evaluation of Associated Factors. <i>AIDS Patient Care and STDs</i> , 2014, 28, 524-529.	1.1	16
40	Effectiveness of Mindfulness-Based Cognitive Therapy on the Quality of Life, Emotional Status, and CD4 Cell Count of Patients Aging with HIV Infection. <i>AIDS and Behavior</i> , 2014, 18, 676-685.	1.4	61
41	Pulse Wave Velocity as Index of Arterial Stiffness in HIV-Infected Patients Compared With a Healthy Population. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 50-56.	0.9	31
42	Randomised Study to Assess the Efficacy and Safety of Once-Daily Etravirine-Based Regimen as a Switching Strategy in HIV-Infected Patients Receiving a Protease Inhibitor-Containing Regimen. Etraswitch Study. <i>PLoS ONE</i> , 2014, 9, e84676.	1.1	11
43	Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2358-2362.	1.3	28
44	Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1382-1387.	1.3	25
45	Long-term effectiveness of infrared coagulation for the treatment of anal intraepithelial neoplasia grades 2 and 3 in HIV-infected men and women. <i>Aids</i> , 2013, 27, 951-959.	1.0	34
46	A Brief and Feasible Paper-Based Method to Screen for Neurocognitive Impairment in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 585-592.	0.9	26
47	Cost-effectiveness of bazedoxifene versus raloxifene in the treatment of postmenopausal women in Spain. <i>ClinicoEconomics and Outcomes Research</i> , 2013, 5, 327.	0.7	6
48	Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery. <i>Aids</i> , 2012, 26, 2285-2293.	1.0	44
49	Emotional Impact of Premature Aging Symptoms in Long-Term Treated HIV-Infected Subjects. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, e5-e8.	0.9	10
50	Similarly high prevalence of hypovitaminosis D in HIV-infected subjects with and without low bone mineral density. <i>Future Virology</i> , 2012, 7, 1127-1134.	0.9	3
51	Psychological stress is associated with high levels of IL-6 in HIV-1 infected individuals on effective combined antiretroviral treatment. <i>Brain, Behavior, and Immunity</i> , 2012, 26, 568-572.	2.0	35
52	High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy. <i>Antiviral Research</i> , 2012, 96, 65-69.	1.9	39
53	The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype. <i>Retrovirology</i> , 2012, 9, 15.	0.9	8
54	Time of Progression to Osteopenia/Osteoporosis in Chronically HIV-Infected Patients: Screening DXA Scan. <i>PLoS ONE</i> , 2012, 7, e46031.	1.1	16

#	ARTICLE	IF	CITATIONS
55	Effect of an induction period of pegylated interferon- α 2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study. <i>Antiviral Therapy</i> , 2011, 16, 833-841.	0.6	3
56	Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?. <i>Journal of NeuroVirology</i> , 2010, 16, 208-218.	1.0	13
57	Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa [®]), in antiretroviral-naïve patients: A 48-week, multicentre, randomized study (Lake Study). <i>Antiviral Research</i> , 2010, 85, 403-408.	1.9	26
58	Validation of estimated renal function measurements compared with the isotopic glomerular filtration rate in an HIV-infected cohort. <i>Antiviral Research</i> , 2010, 88, 347-354.	1.9	26
59	IL28B SNP rs8099917 Is Strongly Associated with Pegylated Interferon- α and Ribavirin Therapy Treatment Failure in HCV/HIV-1 Coinfected Patients. <i>PLoS ONE</i> , 2010, 5, e13771.	1.1	71
60	Nadir CD4 T Cell Count as Predictor and High CD4 T Cell Intrinsic Apoptosis as Final Mechanism of Poor CD4 T Cell Recovery in Virologically Suppressed HIV-1 Infected Patients: Clinical Implications. <i>Clinical Infectious Diseases</i> , 2010, 50, 1300-1308.	2.9	133
61	CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART. <i>Aids</i> , 2010, 24, 959-968.	1.0	114
62	High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. <i>Aids</i> , 2010, 24, 2827-2833.	1.0	140
63	Mild Improvement in Mitochondrial Function After a 3-Year Antiretroviral Treatment Interruption Despite Persistent Impairment of Mitochondrial DNA Content. <i>Current HIV Research</i> , 2010, 8, 379-385.	0.2	2
64	Saquinavir/Ritonavir Monotherapy as a New Nucleoside-Sparing Maintenance Strategy in Long-Term Virologically Suppressed HIV-1 Infected Patients. <i>Current HIV Research</i> , 2010, 8, 467-470.	0.2	4
65	Four-Year Safety with Polyacrylamide Hydrogel to Correct Antiretroviral-Related Facial Lipoatrophy. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 451-455.	0.5	27
66	Improvement of Mitochondrial Toxicity in Patients Receiving a Nucleoside Reverse Transcriptase Inhibitor-Sparing Strategy: Results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA). <i>Clinical Infectious Diseases</i> , 2009, 49, 892-900.	2.9	41
67	HIV-1 Infection in Subjects Older than 70: A Multicenter Cross-Sectional Assessment in Catalonia, Spain. <i>Current HIV Research</i> , 2009, 7, 597-600.	0.2	28
68	Epistasis among Deleterious Mutations in the HIV-1 Protease. <i>Journal of Molecular Biology</i> , 2009, 392, 243-250.	2.0	27
69	Low Levels of Adherence to Antiretroviral Therapy in HIV-1 Infected Women with Menstrual Disorders. <i>AIDS Patient Care and STDs</i> , 2009, 23, 463-468.	1.1	10
70	Accuracy of Simple Biochemical Tests in Identifying Liver Fibrosis in Patients Co-Infected With Human Immunodeficiency Virus and Hepatitis C Virus. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 339-345.	2.4	36
71	Increased Peripheral Proinflammatory Cytokines in HIV-1 Infected Patients With Prolonged Viral Suppression Suffering From High Psychological Stress. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 427-428.	0.9	2
72	Unboosted Atazanavir Plus Co-formulated Lamivudine/Abacavir as a Ritonavir-Sparing Simplification Strategy in Routine Clinical Practice. <i>HIV Clinical Trials</i> , 2009, 10, 129-134.	2.0	10

#	ARTICLE	IF	CITATIONS
73	Long-Term Effectiveness and Safety Outcomes in HIV-1-Infected Patients After a Median Time of 6 Years on Nevirapine. <i>Current HIV Research</i> , 2009, 7, 526-532.	0.2	12
74	Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study. <i>HIV Medicine</i> , 2008, 9, 508-513.	1.0	8
75	Transient Treatment Exclusively Containing Nucleoside Analogue Reverse Transcriptase Inhibitors in Highly Antiretroviral-Experienced Patients Preserves Viral Benefit When a Fully Active Therapy Was Initiated. <i>HIV Clinical Trials</i> , 2008, 9, 387-398.	2.0	7
76	Nadir CD4 Cell Count Predicts Neurocognitive Impairment in HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 1301-1307.	0.5	87
77	Darunavir Inhibitory Quotient Predicts the 48-Week Virological Response to Darunavir-Based Salvage Therapy in Human Immunodeficiency Virus-Infected Protease Inhibitor-Experienced Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3928-3932.	1.4	24
78	Association between HIV replication and cholesterol in peripheral blood mononuclear cells in HIV-infected patients interrupting HAART. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 400-404.	1.3	11
79	Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfecting patients. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2007, 19, 138-145.	0.6	46
80	Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. <i>Aids</i> , 2007, 21, 169-178.	1.0	74
81	Hill A, Moyle G. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials. <i>HIV Med</i> 2007; 8: 259-264. <i>HIV Medicine</i> , 2007, 8, 568-570.	1.0	3
82	The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy. <i>Aids</i> , 2006, 20, 619-621.	1.0	28
83	Characterization of a new circulating recombinant form comprising HIV-1 subtypes C and B in southern Brazil. <i>Aids</i> , 2006, 20, 2011-2019.	1.0	132
84	Long-Term Safety and Efficacy of Nevirapine-Based Approaches in HIV Type 1-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 321-329.	0.5	48
85	Reconstructive Treatment for Antiretroviral-Associated Facial Lipoatrophy: A Prospective Study Comparing Autologous Fat and Synthetic Substances. <i>AIDS Patient Care and STDs</i> , 2006, 20, 829-837.	1.1	48
86	Long-Term Neuropsychiatric Disorders on Efavirenz-Based Approaches. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 38, 560-565.	0.9	151